Search results
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
NBC 17 Raleigh· 1 day ago...Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an oral presentation at the American Society of Clinical Oncology...is the first site-specific conjugated novel ADC targeting Nectin-4 developed by Mabwell using...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
The Yuma Sun· 2 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of...
Morningstar· 1 day agoROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and< ...
Mirae Asset Global Investments Co. Ltd. Increases Stock Holdings in Kymera Therapeutics, Inc....
ETF DAILY NEWS· 13 hours ago(NASDAQ:KYMR – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). Mirae ...
Huize Partners with Ruihua Health Assurance to Launch “Darwin Critical Care No.9” – A Customized...
Morningstar· 2 weeks agoSHENZHEN, China, April 15, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting ...
Vontobel Holding Ltd. Takes $2.58 Million Position in Replimune Group, Inc. (NASDAQ:REPL)
ETF DAILY NEWS· 1 week agoVontobel Holding Ltd. bought a new position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 3 days agoThe acquisition will add MorphoSys’s pelabresib (late-stage BET inhibitor for myelofibrosis) and...
Needham & Company LLC Reaffirms “Buy” Rating for Merus (NASDAQ:MRUS)
ETF DAILY NEWS· 2 weeks agoNeedham & Company LLC reiterated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research report report published on Thursday morning, Benzinga reports. The firm currently ...
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug...
Digital Journal· 3 days ago...US EPA Registration of TWO New Cutting-Edge Antimicrobial Technologies Linde De-captivates Air Separation Unit and Extends Agreement with China South Steel, Member of China Baowu Steel Group Western Alaska Minerals Announces Upsize to Brokered Offering...
BioInvent International AB: Interim Report January-March 2024
Digital Journal· 2 days agoThe Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many...